Biocon stock faces mixed Q2 as profit drops 52 percent

Biocon reported a mixed second quarter for the period ended September 30, 2026, with consolidated net profit falling 52 percent year over year to INR 41 crore while revenue from operations rose 2 percent to INR 4,389 crore. Business Standard reported the results on November 5 and said EBITDA declined 7 percent to INR 865 crore.

The company said more than USD 100 million in new contracts and major US payer wins supported commercialized products, while demand for Insulin Glargine remained strong. Regulatory approvals for the Yesintek autoinjector in the United States and Canada also added to the quarter's product milestones.

Second-half growth rests on launches

Management expects a stronger second half of fiscal 2027, supported by recently launched biosimilars, higher insulin demand and the recognition of shipments delayed beyond September. Business Standard reported that the affected revenue was subsequently booked in October, while also citing expectations for faster biosimilar growth from Yesafili and Bosaya/Okelso.

Biocon also secured a 10-year Pertuzumab partnership in Brazil with a total contract value of about USD 400 million. The company said its Pertuzumab biosimilar had received a recommendation under the European Medicines Agency's tailored clinical development pathway, while the second Insulin Glargine fill-finish line in Malaysia had begun commercial supplies.

Biocon stock at the latest quote

Biocon stock traded at INR 371 on the Bombay Stock Exchange at 3:29 p.m. IST on Thursday, November 12, 2026. The quote is a latest exchange price and is not compared here with a Xetra closing price.

Biocon's business profile

Biocon is an Indian biopharmaceutical company developing medicines from drug discovery through drug delivery. Its activities include biosimilars, generics, insulin products and research services, with products reaching more than 120 countries. The company focuses on making therapies for serious diseases more affordable and accessible.

Investors can follow broader Indian market developments through the BSE Sensex.

For further company-specific coverage, see More news and analyses on Biocon stock.